Inovio Pharma - INO Net Assets per Single Share

Inovio Pharmaceuticals (INO) is strengthening its position through unique electroporation patents and progress in registering a drug for a rare respiratory disease. The share price visualized below, currently at 0.05, is coupled with high revenue volatility, as the company has not yet reached the stage of stable sales. The business model relies on the efficiency of the Cellectra system and the success of DNA vaccine trials.

To find a balance between cost and business quality, it is essential to evaluate the ratio of equity to the number of shares, which determines the real intrinsic value of a single security. This book value per share metric reflects the capitalization efficiency of Inovio Pharmaceuticals (INO) amid the development of the INO-3107 drug and the implementation of the Cellectra platform, allowing investors to distinguish fundamental asset growth from speculative expectations.